Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth

By Douglas Petersen  |    May 18, 2023
May is World Trade Month — an opportunity to remind the Biden Administration of the importance of international trade. America’s biopharmaceutical industry, and the hundreds of thousands of Americans...   Read More

Setting the record straight on the Bayh-Dole Act and March-in

By Megan Van Etten  |    May 10, 2023
The National Institutes of Health (NIH) recently made the right decision to uphold the Bayh-Dole Act and not seize patent rights on an innovative medicine by exploiting part of the law known as the...   Read More

World IP Day 2023: Celebrating women leaders in innovation

By Megan Van Etten  |    April 26, 2023
Today PhRMA joins with innovators around the globe to recognize World IP Day and celebrate biopharmaceutical innovators who dedicate their lives to bringing new treatments and cures to patients. It’s...   Read More

What they are saying: Experts reinforce that TRIPS waiver expansion is harmful and unnecessary

By Megan Van Etten  |    April 13, 2023
At the direction of the U.S. Trade Representative, the U.S. International Trade Commission (USTIC) is investigating the impact of a proposed waiver of intellectual property (IP) protections for...   Read More

New global analysis shows patient access challenges around the world

By Richard Kane  |    April 12, 2023
Today PhRMA released a new report that analyzes the share of new medicines that are available in over 70 countries and how long patients wait to receive them. The Global Access to New Medicines...   Read More

PhRMA provides comments and testimony to USITC investigation on COVID-19 medicines and the TRIPS Agreement

By Kevin Haninger  |    March 30, 2023
At the request of the U.S. Trade Representative, the U.S. International Trade Commission (USITC) is conducting an investigation and will issue an accompanying report concerning the TRIPS Agreement...   Read More

U.S. biopharmaceutical exports support jobs, innovation

By Brian Picone  |    March 20, 2023
The U.S. Census Bureau and the U.S. Bureau of Economic Analysis recently published annual trade data indicating that U.S. exports of goods exceeded $2 trillion in 2022. According to the report, U.S....   Read More

Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?

By Douglas Petersen  |    March 13, 2023
In December 2022, the United States launched negotiations for the Indo-Pacific Economic Framework (IPEF) with thirteen countries throughout the Indo-Pacific region, including Australia, India,...   Read More

PhRMA submits comments to USPTO highlighting important role of patent system in medicine development

By Megan Van Etten  |    February 23, 2023
PhRMA responded to the U.S. Patent and Trademark Office’s (USPTO) request for comments regarding USPTO initiatives to ensure the robustness and reliability of patent rights.   Read More

U.S. must address IP and market access barriers abroad to protect American innovation

By Ernest Kawka  |    January 31, 2023
PhRMA recently submitted comments to the Office of the U.S. Trade Representative (USTR)’s 2023 Special 301 Report. The comments highlight foreign government actions and policies that undermine...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates